Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
David L Kendler & Kenneth Shawn Davison. (2010) Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation. Orthopedic Research and Reviews 2, pages 49-69.
Read now
Read now
Darko Kastelan, Tonko Vlak, Petar Lozo, Marina Gradiser, Sime Mijic, Tatjana Nikolic, Blazenka Miskic, Dolores Car, Gordana Tajsic, Tina Dusek, Zrinka Jajic, Frane Grubisic, Tamara Poljicanin, Miro Bakula, Fedja Dzubur, Matilda Strizak-Ujevic, Mira Kadojic, Maja Radman, Maja Vugrinec, Zeljka Kuster, Marijeta Pekez, Endi Radovic, Ljubica Labar, Zeljka Crncevic-Orlic & Mirko Korsic. (2010) Health-Related Quality of Life Among Patients with Postmenopausal Osteoporosis Treated with Weekly and Monthly Bisphosphonates. Endocrine Research 35:4, pages 165-173.
Read now
Read now
John Sunyecz. (2008) Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clinical Interventions in Aging 3:4, pages 611-627.
Read now
Read now
Natasha Jordan, Maurice Barry & Eithne Murphy. (2006) Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clinical Interventions in Aging 1:4, pages 377-387.
Read now
Read now
Articles from other publishers (46)
George A Wells, Shu-Ching Hsieh, Carine Zheng, Joan Peterson, Wenfei Liu, Shannon E Kelly & Peter Tugwell. (2022) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2022:7.
Crossref
Crossref
Pawel Szulc, Douglas C. Bauer & Richard Eastell. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1545
1588
.
Michael R. McClung & Frank H. Ebetino. (2020) History of risedronate. Bone 137, pages 115407.
Crossref
Crossref
Sabashini K Ramchand, Natalie L David, Benjamin Z Leder & Joy N Tsai. (2020) Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT. The Journal of Clinical Endocrinology & Metabolism 105:3, pages 890-897.
Crossref
Crossref
David Kendler, Arkadi Chines, Patricia Clark, Peter R Ebeling, Michael McClung, Yumie Rhee, Shuang Huang & Robert Kees Stad. (2020) Bone Mineral Density After Transitioning From Denosumab to Alendronate. The Journal of Clinical Endocrinology & Metabolism 105:3, pages e255-e264.
Crossref
Crossref
Najia Siddique, Nessa Fallon, Georgina Steen, James B. Walsh & Miriam C. Casey. (2018) Treatment of osteoporosis with recombinant parathyroid hormone, utilisation of total body DXA to observe treatment effects on total body composition and factors determining response to therapy. Irish Journal of Medical Science (1971 -) 188:2, pages 505-515.
Crossref
Crossref
P.D. Miller, G. Hattersley, E. Lau, L.A. Fitzpatrick, A.G. Harris, G.C. Williams, M.-Y. Hu, B.J. Riis, L. Russo & C. Christiansen. (2019) Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. Bone 120, pages 137-140.
Crossref
Crossref
Gui‐Feng Liu, Zong‐Qiang Wang, Lin Liu, Bu‐Tian Zhang, Ying‐Ying Miao & Shao‐Nan Yu. (2018) A network meta‐analysis on the short‐term efficacy and adverse events of different anti‐osteoporosis drugs for the treatment of postmenopausal osteoporosis. Journal of Cellular Biochemistry 119:6, pages 4469-4481.
Crossref
Crossref
P. Szulc, K. Naylor, N. R. Hoyle, R. Eastell & E. T. Leary. (2017) Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporosis International 28:9, pages 2541-2556.
Crossref
Crossref
A. Diez-Perez, K. E. Naylor, B. Abrahamsen, D. Agnusdei, M. L. Brandi, C. Cooper, E. Dennison, E. F. Eriksen, D. T. Gold, N. Guañabens, P. Hadji, M. Hiligsmann, R. Horne, R. Josse, J. A. Kanis, B. Obermayer-Pietsch, D. Prieto-Alhambra, J.-Y. Reginster, R. Rizzoli, S. Silverman, M. C. Zillikens & R. Eastell. (2017) International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporosis International 28:3, pages 767-774.
Crossref
Crossref
M. W. Aref, E. M. B. McNerny, D. Brown, K. J. Jepsen & M. R. Allen. (2016) Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes. Osteoporosis International 27:12, pages 3637-3643.
Crossref
Crossref
Benjamin Z. Leder, Joy N. Tsai, Robert M. Neer, Alexander V. Uihlein, Paul M. Wallace & Sherri-Ann M. Burnett-Bowie. (2016) Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. Journal of Clinical Densitometry 19:3, pages 346-351.
Crossref
Crossref
Samuel D. Vasikaran & S. A. Paul Chubb. (2016) The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. Endocrine 52:2, pages 222-225.
Crossref
Crossref
Jun Iwamoto & Tetsuya Takada. (2015) Effect of minodronate on the speed of sound of the calcaneus in postmenopausal women with an increased risk of fractures: A clinical practice-based observational study. Journal of the Chinese Medical Association 78:10, pages 591-596.
Crossref
Crossref
Ta-Wei Tai, Fong-Chin Su, Ching-Yu Chen, I-Ming Jou & Chiou-Feng Lin. (2014) Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors. Bone 67, pages 166-174.
Crossref
Crossref
I. Baxter, A. Rogers, R. Eastell & N. Peel. (2012) Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporosis International 24:3, pages 941-947.
Crossref
Crossref
Pawel Szulc & Douglas C. Bauer. 2013. Osteoporosis. Osteoporosis
1573
1610
.
Sung Jin Bae, Beom-Jun Kim, Kyeong Hye Lim, Seung Hun Lee, Hong Kyu Kim, Ghi Su Kim & Jung-Min Koh. (2012) Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. Journal of Bone and Mineral Metabolism 30:5, pages 588-595.
Crossref
Crossref
Pawel Szulc. (2012) The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clinical Biochemistry 45:12, pages 907-919.
Crossref
Crossref
Richard Eastell, David M. Reid, Slobodan Vukicevic, Kristine E. Ensrud, Andrea Z. LaCroix, John R. Thompson, David D. Thompson & Steven R. Cummings. (2012) Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone 50:5, pages 1135-1140.
Crossref
Crossref
Brian J. GatesShyamal Das. (2012) Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 5, pages CMAMD.S4092.
Crossref
Crossref
Andrew Grey, Mark Bolland, Sumwai Wong, Anne Horne, Greg Gamble & Ian R. Reid. (2012) Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. The Journal of Clinical Endocrinology & Metabolism 97:1, pages 286-292.
Crossref
Crossref
Björn Jobke, Andrew J. Burghardt, Burkhard Muche, Michael Hahn, Jutta Semler, Michael Amling, Sharmila Majumdar & Björn Busse. (2011) Trabecular Reorganization in Consecutive Iliac Crest Biopsies when Switching from Bisphosphonate to Strontium Ranelate Treatment. PLoS ONE 6:8, pages e23638.
Crossref
Crossref
Marc C. Hochberg, Stuart L. Silverman, Charles E. Barr & Paul D. Miller. (2010) The Utility of Changes in Serum Levels of C-Terminal Telopeptide of Type I Collagen in Predicting Patient Response to Oral Monthly Ibandronate Therapy. Journal of Clinical Densitometry 13:2, pages 181-189.
Crossref
Crossref
S. Boonen, R. Kay, C. Cooper, P. Haentjens, D. Vanderschueren, F. Callewaert, K. Milisen & S. Ferrari. (2009) Osteoporosis management: a perspective based on bisphosphonate data from randomised clinical trials and observational databases. International Journal of Clinical Practice 63:12, pages 1792-1804.
Crossref
Crossref
Steven R. Cummings, Javier San Martin, Michael R. McClung, Ethel S. Siris, Richard Eastell, Ian R. Reid, Pierre Delmas, Holly B. Zoog, Matt Austin, Andrea Wang, Stepan Kutilek, Silvano Adami, Jose Zanchetta, Cesar Libanati, Suresh Siddhanti & Claus Christiansen. (2009) Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. New England Journal of Medicine 361:8, pages 756-765.
Crossref
Crossref
A. Sebba. (2008) Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface. Osteoporosis International 20:5, pages 675-686.
Crossref
Crossref
Sherri-Ann M. Burnett-Bowie, Kenneth Saag, Anthony Sebba, Anne E. de Papp, Erluo Chen, Elizabeth Rosenberg & Susan L. Greenspan. (2009) Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates. The Journal of Clinical Endocrinology & Metabolism 94:4, pages 1097-1103.
Crossref
Crossref
Ronald Emkey, Pierre D. Delmas, Michael Bolognese, Joao Lindolfo C. Borges, Felicia Cosman, Sergio Ragi-Eis, Christopher Recknor, Cristiano A. Zerbini, Colin Neate, Farhad Sedarati & Solomon Epstein. (2009) Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study. Clinical Therapeutics 31:4, pages 751-761.
Crossref
Crossref
Jacques P Brown, Richard L Prince, Chad Deal, Robert R Recker, Douglas P Kiel, Luiz H de Gregorio, Peyman Hadji, Lorenz C Hofbauer, Jose M Álvaro-Gracia, Huei Wang, Matthew Austin, Rachel B Wagman, Richard Newmark, Cesar Libanati, Javier San Martin & Henry G Bone. (2009) Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. Journal of Bone and Mineral Research 24:1, pages 153-161.
Crossref
Crossref
A. Díez-Pérez & J. González-Macías. (2008) Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporosis International 19:11.
Crossref
Crossref
Michael SamoszukMichael LeutherNicholas Hoyle. (2008) Role of serum P1NP measurement for monitoring treatment response in osteoporosis. Biomarkers in Medicine 2:5, pages 495-508.
Crossref
Crossref
Ankur A KarnikJoan M von Feldt. (2008) Osteoporosis in the elderly. Aging Health 4:4, pages 351-363.
Crossref
Crossref
Margery L. Gass, Risa Kagan, Joseph D. Kohles & Mark G. Martens. (2008) Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 15:4, pages 667-675.
Crossref
Crossref
Patrick G Clay, Laura E Voss, Charlott Williams & Eric C Daume. (2008) Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons. Annals of Pharmacotherapy 42:5, pages 670-679.
Crossref
Crossref
PAWEL SZULC & PIERRE D. DELMAS. 2008. Osteoporosis. Osteoporosis
1519
1545
.
Hosam K. Kamel. (2007) Update on Osteoporosis Management in Long-term Care: Focus on Bisphosphonates. Journal of the American Medical Directors Association 8:7, pages 434-440.
Crossref
Crossref
Ann Cranney & Jonathan D. Adachi. (2007) Bisphosphonates for the Treatment of Postmenopausal Osteoporosis: An Update. Clinical Reviews in Bone and Mineral Metabolism 5:3, pages 145-152.
Crossref
Crossref
Dennis M. Black, Pierre D. Delmas, Richard Eastell, Ian R. Reid, Steven Boonen, Jane A. Cauley, Felicia Cosman, Péter Lakatos, Ping Chung Leung, Zulema Man, Carlos Mautalen, Peter Mesenbrink, Huilin Hu, John Caminis, Karen Tong, Theresa Rosario-Jansen, Joel Krasnow, Trisha F. Hue, Deborah Sellmeyer, Erik Fink Eriksen & Steven R. Cummings. (2007) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine 356:18, pages 1809-1822.
Crossref
Crossref
Jean-Yves Reginster, Olivier Malaise, Audrey Neuprez, Victor-Emmanuel Jouret & Pierre Close. (2007) Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis. Drugs & Aging 24:5, pages 351-359.
Crossref
Crossref
Aysegul Atmaca & Olcay Gedik. (2006) Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis. Advances in Therapy 23:6, pages 842-853.
Crossref
Crossref
Matthew R. Allen, Ken Iwata, Roger Phipps & David B. Burr. (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:4, pages 872-879.
Crossref
Crossref
Kailas B. Sawant & Michael P. Jennings. (2006) Efficient Total Syntheses and Structural Verification of Both Diospongins A and B via a Common δ-Lactone Intermediate. The Journal of Organic Chemistry 71:20, pages 7911-7914.
Crossref
Crossref
Stuart L. Silverman. (2006) Lessons from osteoporosis clinical trials. Alzheimer's & Dementia 2:3, pages 155-159.
Crossref
Crossref
Sydney Lou Bonnick & Lee Shulman. (2006) Monitoring Osteoporosis Therapy: Bone Mineral Density, Bone Turnover Markers, or Both?. The American Journal of Medicine 119:4, pages S25-S31.
Crossref
Crossref
Clifford J Rosen, Marc C Hochberg, Sydney Lou Bonnick, Michael McClung, Paul Miller, Susan Broy, Risa Kagan, Erluo Chen, Richard Petruschke, Desmond E Thompson & Anne E de Papp. (2005) How to Interpret Surrogate Markers of Efficacy in Osteoporosis. Journal of Bone and Mineral Research 20:7, pages 1263-1264.
Crossref
Crossref